Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: A prospective cohort study

•We report an amended thromboprophylactic strategy using apixaban rather than low-molecular-weight heparin for high thrombotic risk myeloma patients.•No thrombotic events are reported in patients receiving prophylactic apixaban.•Major bleeding occurred in 1.2% patients on prophylactic apixaban.•Apix...

Full description

Saved in:
Bibliographic Details
Published inThrombosis research Vol. 213; pp. 27 - 29
Main Authors Sayar, Zara, Gates, Carolyn, Bristogiannis, Sotirios, Patel, Aisha, Ogunbiyi, Margaret Olabisi, Tailor, Anish, Yong, Kwee, Thomas, Mari
Format Journal Article
LanguageEnglish
Published United States Elsevier Ltd 01.05.2022
Subjects
Anticoagulants - therapeutic use
Humans
Multiple Myeloma - complications
Multiple Myeloma - drug therapy
Prospective Studies
Pyrazoles
Pyridones - adverse effects
Venous Thromboembolism - drug therapy
Venous Thromboembolism - prevention & control
Online AccessGet full text

Cover

More Information
Summary:•We report an amended thromboprophylactic strategy using apixaban rather than low-molecular-weight heparin for high thrombotic risk myeloma patients.•No thrombotic events are reported in patients receiving prophylactic apixaban.•Major bleeding occurred in 1.2% patients on prophylactic apixaban.•Apixaban appears to be an effective and safe alternative to low-molecular-weight-heparin as thromboprophylaxis in myeloma.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0049-3848
1879-2472
DOI:10.1016/j.thromres.2022.03.001